McKesson agrees to settle drug pricing complaints
- Share via
McKesson Corp. agreed to pay $350 million to settle claims it fraudulently inflated the price of more than 400 prescription drugs.
McKesson, the largest U.S. medicine distributor, will also set aside $143 million to settle claims from federal and state health programs. The settlement and the reserve will result in an after-tax charge of $311 million, or $1.14 a share, in the current quarter, the company said. It admitted no wrongdoing.
The claims stem from 2005 lawsuits by the New England Carpenters Health Benefits Fund and other plaintiffs accusing San Francisco-based McKesson of conspiring with Hearst Corp.’s First DataBank, a drug-price publisher, to push up the amount pharmacies pocket on drugs and to increase the wholesaler’s share of the business.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
